替吉奥胶囊联合腹腔灌注顺铂和白介素-Ⅱ治疗胃癌所致腹腔积液临床观察

Clinical observation of Gimeracfl and Oteracil Porassium Capsules combined with intraperitoneal perfusion chemotherapy for the patients of stomach cancer with malignant ascites

目的观察替吉奥胶囊联合腹腔灌注顺铂和白介素-Ⅱ治疗晚期胃癌所致腹腔积液近期疗效、临床受益率和副反应。方法采用中心静脉导管以腹穿术行腹腔内置管，进行持续腹腔引流，引流量1000～1500ml／d，引流3～5d，而后经中心静脉导管注入含顺铂、白介素-Ⅱ的生理盐水200ml。48h后打开引流管，引流残留腹水。从治疗第1天起口服替吉奥胶囊40—50mg，2次／d，第1—28天，休息14d再进行下一周期治疗。共治疗2周期。结果患者治疗后总有效率87．5％；临床受益率为90．6％。治疗副反应主要为骨髓抑制和消化道症状。结论替吉奥胶囊联合腹腔灌注顺铂和白介素-Ⅱ治疗晚期胃癌所致腹腔积液，疗效确切，患者可耐受。

Objective To evaluate the efficacy and toxicity of Gimeracil and Oteracil Porassium Capsules combined with intraperitoneal perfusion chemotherapy for the patients of stomach cancer with malignant ascites. Methods Thirty-two patients of stomach cancer with malignant ascites were received the following treatment ： infusing the 0. 9% NS 200 ml of DDP and recomposed human interleukin- Ⅱ, then every patient took orally Gimeracil and Oteracil Porassium Capsules 40-50 mg/d, hid from the first day to twenth-eight day. Results The total response rate was 87. 5% and the clinical benefition rate was 90. 6%. The main toxicity was hone marrow suppression and gastroenteric. Conclusion The Gimeracil and Oteracil Porassium Capsules combined with intraperitoneal perfusion chemotherapy is well tolerated and effective in the patients of stomach cancer with malignant ascites.